OncoHost Breakthrough Enables Integration of Serum and Plasma Proteomic Data for Enhanced Cancer Biomarker Research

Original source here

OncoHost Breakthrough Enables Integration of Serum and Plasma Proteomic Data for Enhanced Cancer Biomarker Research

Key Insights

• OncoHost published a landmark study in JPBA introducing a validated computational framework that harmonizes serum and plasma proteomic datasets, overcoming a long-standing analytical barrier in biomarker research.

• The multi-institutional study analyzed 7,289 proteins across 177 matched serum-plasma sample pairs from cancer patients, finding 91.6% of proteins showed statistically significant correlation (p < 0.05) between specimen types.

• The bridging methodology was successfully validated using OncoHost's PROphet® AI platform for non-small cell lung cancer immunotherapy prediction, maintaining predictive accuracy when applied to transformed serum data.

OncoHostSearch company, a precision oncology technology company, has published groundbreaking research in the Journal of Pharmaceutical and Biomedical Analysis (JPBA) that addresses a fundamental challenge in proteomic biomarker research. The study introduces a validated computational framework capable of harmonizing serum and plasma proteomic datasets—specimen types that have historically been considered analytically non-comparable due to biological and pre-analytical differences.

The multi-institutional collaboration included leading researchers from the National Cancer InstituteView company profile (NCI), Yale School of MedicineView company profile, Heidelberg University HospitalView company profile, and biomarker development company ions.bioSearch company, working alongside OncoHostSearch company's scientific team to develop this innovative approach.

Overcoming Technical Barriers in Proteomic Research

Serum and plasma are widely used in clinical research and biobanking, but differences in sample preparation have resulted in proteomic variations that limited direct comparison and data integration across specimen types. This technical divide has forced researchers to analyze large retrospective cohorts from each specimen type separately, limiting the scope and power of biomarker studies.

The research team performed high-throughput proteomic profiling of 7,289 proteins using the SomaScan® platform on 177 matched serum-plasma sample pairs from cancerSearch disease patients across three independent cohorts. The results demonstrated remarkable consistency, with 91.6% of proteins showing statistically significant correlation (p < 0.05) between serum and plasma measurements.

Using the matched sample pairs, researchers derived linear scaling factors that remained consistent across all cohorts, supporting the generalizability and robustness of the bridging methodology. This systematic approach enables researchers to transform measurements between specimen types while preserving the underlying biological signal.

"This work addresses a longstanding challenge in proteomic biomarker research," said Coren Lahav, MSc, Senior Data Scientist and lead author of the study. "By enabling systematic transformation between serum and plasma measurements, we can leverage previously siloed datasets. This strengthens analytical robustness, improves clinical sample flexibility, and supports scalable multi-cohort validation."

Clinical Validation Through AI-Powered Platform

The study's clinical relevance was validated using OncoHostSearch company's PROphet® platform, an AI-powered, plasma proteomics-based model designed to predict immunotherapy outcomes in patients with non-small cell lung cancerSearch disease (NSCLCSearch disease). When the PROphetSearch drug model was applied to scaled serum proteomic measurements, it maintained its predictive accuracy.

Clinical benefit classification and survival stratification derived from transformed serum data were comparable to those generated from plasma, confirming that the bridging methodology preserves the underlying biological signal necessary for accurate clinical predictions.

"This milestone advances the field of liquid proteomics," said Ofer Sharon, MD, CEO of OncoHostSearch company. "Demonstrating that plasma-based predictive models can be reliably extended to serum through rigorous harmonization reinforces the robustness of our approach and supports broader clinical implementation. The ability to generalize across specimen types enhances the utility of proteomic diagnostics and supports wider adoption in precision oncology."

Implications for Future Research

Beyond immediate dataset alignment, the study provides a structured methodology for future sample-type standardization, including compatibility across tube types and biological matrices. This capability may unlock valuable serum-based cohorts that were previously unusable for discovery and validation initiatives.

The framework allows researchers to combine heterogeneous cohorts, accelerating biomarker discovery and validation efforts while enhancing both the analytical depth and translational applicability of proteomic research. As proteomics become increasingly central to precision oncology, systematic standardization approaches will be essential for advancing reproducible and scalable biomarker development.

The breakthrough creates new flexibility in sample utilization and supports the broader clinical implementation of proteomic diagnostics, potentially accelerating the development of precision medicine tools across multiple cancerSearch disease types and treatment modalities.

‍